Collaboration is a constant theme for biotech companies, from inception to exit: researchers work together to generate novel ideas, young companies work with development and formulation partners, and collaborations between pharmaceutical companies and biotechs are the classic final phase of drug development.
That’s just the tip of the iceberg:
Foundations work together: foundations formed by the families of patients can be the most ardent advocates for getting drugs to market, but that is an expensive process. One solution is for multiple foundations to pitch in to fund the same project. That was the story with CureDuchenne and the Foundation . . . [more]